摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(乙氨基)苯甲酸 | 7409-09-8

中文名称
4-(乙氨基)苯甲酸
中文别名
——
英文名称
4-(ethylamino)benzoic acid
英文别名
4-Ethylaminobenzoesaeure
4-(乙氨基)苯甲酸化学式
CAS
7409-09-8
化学式
C9H11NO2
mdl
——
分子量
165.192
InChiKey
SWXFMMWYVSYQGF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    175 °C
  • 沸点:
    330.9±25.0 °C(Predicted)
  • 密度:
    1?+-.0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    49.3
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S37/39
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2922499990
  • 储存条件:
    室温

SDS

SDS:983501961676d836356c72789e72cc10
查看
Name: 4-(Ethylamino)benzoic acid 97% Material Safety Data Sheet
Synonym:
CAS: 7409-09-8
Section 1 - Chemical Product MSDS Name:4-(Ethylamino)benzoic acid 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
7409-09-8 4-(Ethylamino)benzoic acid 97% unlisted
Hazard Symbols: XI
Risk Phrases: 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 7409-09-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 178 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H11NO2
Molecular Weight: 165

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 7409-09-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(Ethylamino)benzoic acid - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 7409-09-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 7409-09-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 7409-09-8 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(乙氨基)苯甲酸 在 cytochrome P450 CYP199A4 作用下, 反应 20.0h, 生成 对乙酰氨基苯甲酸
    参考文献:
    名称:
    Rhodopseudomonas palustris的细胞色素P450 CYP199A4催化杂原子脱烷基,硫氧化,酰胺和环状半缩醛形成
    摘要:
    细胞色素P450酶在许多生物系统中执行一系列选择性氧化生物转化。细菌酶CYP199A4催化4-甲氧基苯甲酸的氧化脱甲基作用。分子的苯甲酸部分在酶的活性位点结合,从而使对位的官能团保持在血红素铁附近。因此,CYP199A4有可能催化与不同的对位取代的苯甲酸底物(例如硫醚和烷基胺)发生交替的单加氧酶反应。CYP199A4对4-甲基-和4-乙基-硫代苯甲酸的氧化导致硫的氧化。通过CYP199A4进行的4-乙基硫代苯甲酸亚硫酸盐氧化和4-乙基苯甲酸的羟基化具有高对映选择性(> 74%对映体过量)。相比之下,CYP199A4在与4-甲基和4-二甲基氨基苯甲酸形成N-氧化物时催化了专有的氧化N-脱甲基化作用。出乎意料的是,由CYP199A4形成的乙酰胺与4-烷基-和二乙基-氨基苯甲酸的周转中的脱烷基反应竞争。用3,4-亚乙二氧基苯甲酸未观察到氧化脱烷基,仅羟基化形成环状半缩醛。解决了酶的四种底物结合形
    DOI:
    10.1021/acscatal.8b00909
  • 作为产物:
    描述:
    N-乙基-4-氰基苯胺盐酸 作用下, 以 为溶剂, 以90%的产率得到4-(乙氨基)苯甲酸
    参考文献:
    名称:
    [EN] PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS
    [FR] DÉRIVÉS PHÉNYLALANINES ET LEUR UTILISATION COMME MODULATEURS NON PEPTIDIQUES DU RÉCEPTEUR DE GLP-1
    摘要:
    本文提供了非肽类GLP-1受体调节剂化合物,例如,Formula (I)的化合物,包括这些化合物的药物组合物,以及其制备方法。还提供了这些化合物用于治疗代谢紊乱的方法。
    公开号:
    WO2011094890A1
点击查看最新优质反应信息

文献信息

  • Pyrrolidine derivatives
    申请人:——
    公开号:US20020049243A1
    公开(公告)日:2002-04-25
    The present invention relates to pyrrolidine derivatives and dimeric forms and/or pharmaceutically acceptable esters, and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.
    本发明涉及吡咯烷衍生物及其二聚体形式和/或药用可接受的酯和/或盐。这些化合物可用作金属蛋白酶抑制剂,例如锌蛋白酶,特别是锌水解酶,对治疗与血管收缩增加发生相关的疾病状态有效。
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    申请人:Salituro Francesco G.
    公开号:US20100331307A1
    公开(公告)日:2010-12-30
    Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    本文描述了调节丙酮酸激酶M2(PKM2)的化合物和含有这些化合物的组合物。本文还描述了利用调节PKM2的化合物治疗癌症的方法。
  • Reductive and Catalytic Monoalkylation of Primary Amines Using Nitriles as an Alkylating Reagent
    作者:Hironao Sajiki、Takashi Ikawa、Kosaku Hirota
    DOI:10.1021/ol047871o
    日期:2004.12.1
    and catalytic mono-N-alkylation method of both aromatic and aliphatic amines using nitriles as an alkylating agent with Pd/C or Rh/C as a catalyst is described. This method is particularly attractive to provide an environmentally benign and applicable alkylation method of amines without using toxic and corrosive alkylating agents such as alkyl halides and carbonyl compounds.
    [反应:参见正文]描述了使用腈作为烷基化剂,以Pd / C或Rh / C为催化剂的芳香族和脂肪族胺的选择性催化单N-烷基化方法。该方法对于提供一种环境友好的胺的烷基化方法而不使用有毒和腐蚀性的烷基化剂(例如卤代烷和羰基化合物)特别有吸引力。
  • Selective N-alkylation of amines using nitriles under hydrogenation conditions: facile synthesis of secondary and tertiary amines
    作者:Takashi Ikawa、Yuki Fujita、Tomoteru Mizusaki、Sae Betsuin、Haruki Takamatsu、Tomohiro Maegawa、Yasunari Monguchi、Hironao Sajiki
    DOI:10.1039/c1ob06303k
    日期:——
    the one-pot hydrogenation of the nitro group and the reductive alkylation of the amines. While aliphatic amines were effectively converted to the corresponding tertiary amines under Pd/C-catalyzed conditions, Rh/C was a highly effective catalyst for the N-monoalkylation of aliphatic primary amines without over-alkylation to the tertiary amines. Furthermore, the combination of the Rh/C-catalyzed N-monoalkylation
    发现腈是在催化氢化条件下用于胺的选择性N-烷基化的高效烷基化试剂。对于芳族伯胺,相应的仲胺是在以下条件下有选择地获得的:钯/ C催化的氢化条件。尽管使用电子贫乏的芳族胺或庞大的腈显示出对还原烷基化反应的较低反应性,但添加NH 4 OAc增强了反应活性,从而以优异的产率获得了芳族仲胺。在相同的反应条件下,芳族硝基化合物代替芳族伯胺可以通过多胺反应直接转化为仲胺,该反应涉及硝基的一锅加氢和胺的还原烷基化。脂族胺在以下条件下有效地转化为相应的叔胺钯/ C催化的条件, 铑/ C是用于脂族伯胺的N-单烷基化而不会过度烷基化成叔胺的高效催化剂。此外,铑/ C催化的脂肪族伯胺的N-单烷基化反应及其他钯所得仲脂族胺的/ C催化烷基化可以选择性地制备具有三个不同烷基的脂族叔胺。根据机理研究,似乎可以合理地得出以下结论:在反应的第一步中,在胺发生亲核攻击之前,腈被还原为醛亚胺。
  • [EN] SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE HAT SPIROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
    申请人:ABBVIE INC
    公开号:WO2016044770A1
    公开(公告)日:2016-03-24
    Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    具有式(IX)的结构或其立体异构体、互变异构体或药学上可接受的盐的化合物,其中R1、R2a、R2b、R3a、R3b、R4a、R4b、Q1----Q2、R6、R7、A、B、W、x和y如本文所定义,并提供。还提供了包括这些化合物的药物组合物和通过给予这些化合物治疗各种HAT相关疾病或疾病,包括癌症的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐